A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Pliant Therapeutics, Inc.
Genmab
Sotio Biotech Inc.
Dragonfly Therapeutics
PMV Pharmaceuticals, Inc
NeoImmuneTech
Tizona Therapeutics, Inc
Essen Biotech
Eli Lilly and Company
Seagen Inc.
Novartis
Sotio Biotech Inc.
Eli Lilly and Company
Medicenna Therapeutics, Inc.
M.D. Anderson Cancer Center
OncoC4, Inc.
Compugen Ltd
Carisma Therapeutics Inc
NextCure, Inc.
Sellas Life Sciences Group
Eli Lilly and Company
NGM Biopharmaceuticals, Inc
NGM Biopharmaceuticals, Inc
Second Affiliated Hospital of Guangzhou Medical University
ADC Therapeutics S.A.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
Ikena Oncology
Atreca, Inc.
Corvus Pharmaceuticals, Inc.
Fate Therapeutics
Kineta Inc.
M.D. Anderson Cancer Center
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Incyte Corporation
Incyte Corporation
KitovPharma
Daiichi Sankyo